Navigation Links
AMICAS Set to Join Russell 3000 Index
Date:6/17/2009

Inclusion will result in increased visibility within the investment community

BOSTON, June 17 /PRNewswire-FirstCall/ -- AMICAS, Inc. (Nasdaq: AMCS), a leader in image and information management solutions, today announced that it expects to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 26, according to a preliminary list of additions posted June 12 on www.russell.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO )

"AMICAS is a leading independent provider of image and information management solutions for healthcare. As such, we're pleased that AMICAS will become part of the Russell 3000 Index," said Stephen Kahane MD, president, chief executive officer, and chairman of AMICAS. "The Russell indexes have a solid history and reputation as tools for investors to track the market and its various movements and trends. We believe that inclusion in the Russell 3000 Index will result in increased visibility within the investment community and we look forward to executing on our recent combination with Emageon to increase shareholder value."

Annual reconstitution of Russell's U.S. indexes captures the largest U.S. stocks as of the end of May, determined by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily
'/>"/>

SOURCE AMICAS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AMICAS Showcases Vendor-Neutral Archive Solutions at SIIM 2009
2. AMICAS Schedules First Quarter 2009 Earnings Results Conference Call
3. AMICAS Announces General Availability of AMICAS PACS Version 6.0 at HIMSS 2009
4. AMICAS Announces Completion of Merger with Emageon
5. AMICAS Successfully Completes Tender Offer for Shares of Emageon Inc.
6. Australias Healthinc and AMICAS Announce Exclusive Partnership
7. AMICAS Delivers Advanced Integration Framework to Monroe Clinic
8. AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008
9. AMICAS Announces Definitive Agreement to Acquire Emageon Inc.
10. AMICAS Mourns the Passing of Board Member Dr. Phillip Berman
11. AMICAS Schedules Fourth Quarter and 2008 Year End Earnings Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... NEW ORLEANS, Dec. 6 Onyx Pharmaceuticals, ... safety data from the pivotal Phase 2b 003-A1 ... carfilzomib is well-tolerated in heavily pre-treated relapsed and ... today at the ASH/ASCO Joint Symposium at the ... Hematology (ASH) in New Orleans. Enrollment in this ...
(Date:12/6/2009)... the community, in cooperation with the Greater VA Healthcare System in ... year,s attendance is expected to soar to more than 5,000 veterans, ... ... (PRWEB) December 6, 2009 -- Volunteer organizations and members of ... West Los Angeles, will once again create a holiday party. This ...
(Date:12/5/2009)... December 5 The first Football,for Hope Centre ... opened its doors,today (5 December 2009). FIFA President ... Helen Zille, 2010 FIFA World Cup Organising Committee,South ... Association,President Kirsten Nematandani and Executive Mayor of the ...
(Date:12/5/2009)... advanced Technology Center helps companies develop and test their cleaning processes. ... a variety of industries and solve problems for customers relating to ... ... December 5, 2009 -- Midbrook, Inc , a Jackson, MI-based ...
(Date:12/4/2009)... NEW YORK, Dec. 4 Care Investment Trust Inc. ... that its Board of Directors has declared a dividend of $0.17 ... December 22, 2009 to common shareholders of record on December 14, ... ,, Care Investment Trust Inc. is a real estate investment and ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
... 15 The Houston Chapter of the American,Association ... with a donation of $35,000 to advance cancer ... Neuroblastoma Research Program led by surgeon,Eugene Kim. The ... to,block blood vessel growth in neuroblastoma, a deadly ...
... play role in immune, inflammatory processes, study says ... psoriasis have higher levels of the obesity-related hormone leptin ... Taiwanese study included 77 psoriasis patients and a control ... The researchers gathered health information about the participants and ...
... The board of directors of,Eli Lilly and Company (NYSE: ... in,its quarterly dividend. The board declared a dividend for ... common stock. This raises the,annual indicated rate to $1.96 ... company has increased the dividend payment. , ...
... Children & High School Student Volunteers Collaborate in Musical ... N.J. and HAWTHORNE, N.J., Dec. 15 ... performing arts organization and conservatory bringing together individuals with ... is pleased to announce that its members, all children ...
... are "addicted" to a family of proteins produced by ... halts cell proliferation in the deadliest cancer of the ... of California, Berkeley scientists at the American Society for ... in San Francisco. , In 30-60 percent of human ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today provided the ... , The Food and Drug Administration (FDA) ... The new draft guidance is open for public comment, ... generic applicants beyond the in vitro dissolution testing ...
Other Medicine News:Health News:Drilling Engineers Donate $35,000 to Texas Children's Hospital 2Health News:Obesity-Related Hormone Tied to Psoriasis 2Health News:Sharing The Arts & Ridgewood High School Present Musical Production of Charlie and The Chocolate Factory 2Health News:Stopping ovarian cancer by blocking proteins coded by notorious gene 2Health News:ViroPharma Provides Update on Vancocin(R) 2Health News:ViroPharma Provides Update on Vancocin(R) 3Health News:ViroPharma Provides Update on Vancocin(R) 4
(Date:12/4/2009)... Hospira, Inc. (NYSE: HSP ), a leading ... the launch of its next-generation 50 mL and 100 ... and now offers a complete size range (50 mL ... product. The launch of the 50 mL and 100 ...
(Date:12/4/2009)... Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced today ... study demonstrating the effectiveness of Valortim® in an ... (NZW) rabbit. The data are being presented ...
(Date:12/4/2009)... 4 Axsun Technologies, Inc., a wholly-owned subsidiary of ... initial development and successful testing of a novel integrated ... this proprietary optical engine design raises the bar on ... for swept source OCT light sources. This approach ...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Abbott Hosts Conference Call for Third Quarter Earnings 14252 1Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 1Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 2Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 3Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 4Babies see it coming 58252 1Babies see it coming 58252 2
... WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- The,following is a ... and executive order: , East Room , 2:39 P.M. ... America is a,nation that leads the world in science ... in,medicine that could save lives and cure diseases. America ...
... 2007 /PRNewswire-USNewswire/ -- Democratic,National Committee Chairman Howard Dean ... again put politics ahead,of science by vetoing the ... legislation, providing federal funding for life-saving,embryonic stem cell ... and passed both the House and Senate with,bipartisan ...
Other Medicine Technology:Remarks by President Bush on Stem Cell Veto and Executive Order 2Remarks by President Bush on Stem Cell Veto and Executive Order 3Remarks by President Bush on Stem Cell Veto and Executive Order 4Remarks by President Bush on Stem Cell Veto and Executive Order 5Remarks by President Bush on Stem Cell Veto and Executive Order 6Dean: President Bush Has Turned His Back on the American People 2
... The Mayfield 2000 series radiolucent headrest system ... intraoperative digital subtraction angiography. This system is ... skull clamp and the Mayfield radiolucent base ... designed for patient positioning in the prone ...
Bunnel hand drill with Jacobs chuck, chuck size 4 mm....
Hudson hand drill with extension piece....
Sighting and visualization system of the digital operating suite. The platform that links navigation, and intra-operative imaging to form the ultimate surgical workstation....
Medicine Products: